Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000740:Anemia / Q000139:chemically induced; D001772:Blood Cell Count; D001792:Blood Platelets; D001859:Bone Neoplasms / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006452:Hemoglobinometry; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009325:Nausea / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine